Abbott Initiates U.S. Study of Absolute Pro(TM) Peripheral Stent System for Iliac Artery Disease

MOBILITY trial showcases company's leadership in developing innovative endovascular treatment options

ABBOTT PARK, Ill., April 1 (HSMN NewsFeed) -- Abbott (NYSE: ABT) today announced the initiation of MOBILITY, a clinical trial studying the safety and efficacy of the Absolute Pro(TM) Peripheral Self-Expanding Stent System in patients with iliac artery disease. Iliac artery disease is a form of peripheral artery disease (PAD) that affects the lower extremities. The first patient was enrolled into the MOBILITY trial by John Campbell, M.D., assistant professor of surgery and medicine, West Virginia University School of Medicine, Charleston Division, at the Charleston Area Medical Center in Charleston, W. Va.

"Iliac artery occlusive disease has the potential not only to have a significant impact on a patient's ability to carry on daily activities, but it also can be an early sign of plaque buildup in other parts of the body," said Manish Mehta, M.D., M.P.H., FACS, director of Endovascular Services, The Vascular Institute for Health and Disease, Albany Medical Center in Albany, N.Y., and co-principal investigator of the MOBILITY trial. "The lower extremity discomfort and fatigue with walking and exercise caused by this debilitating disease can tremendously impact a patient's overall quality of life, making it critical to find effective treatments. Data from the MOBILITY trial will be an important addition to iliac stenting research."

Full article >> http://salesandmarketingnetwork.com/news_release.php?pipe=0000ac177000191&ID=2027709